Where does Centerline Biomedical, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Centerline Biomedical, Inc. ranks #25,975 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Centerline Biomedical, Inc. hold?

Centerline Biomedical, Inc. holds 10 US utility patents granted between 2021 and 2024, spanning 7 technology areas.

What is Centerline Biomedical, Inc.'s Innovation Score?

Centerline Biomedical, Inc. has an Innovation Score of 50.9 out of 100 (top 12% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Centerline Biomedical, Inc. focus on?

Centerline Biomedical, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 8 patents, ranking #2,086 of 7,127 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Centerline Biomedical, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Centerline Biomedical, Inc..

What does claim depth mean for Centerline Biomedical, Inc.'s patents?

Centerline Biomedical, Inc.'s patents average 22.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Centerline Biomedical, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Centerline Biomedical, Inc.

USPTO PatentsView assignee record - 10 granted patents across 7 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Centerline ranks #25,975 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 7 technology areas.

#25,975
of 49,997 US assignees by volume: Top 12%
by Innovation Score (50.9/100): 22.1
avg claims per patent

USPTO PatentsView assignee plate

Corpus R25975 · US Corporation #25,975 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 10 grants
MID-PACK #25,975/49,997
PHOTO-FINISH Celeritasworks
CPC-NARROW A61B · 7 areas
INNOV-PAR 50.9/100
CLAIMS-DENSE 22.1 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2021–2024 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Celeritasworks, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Centerline’s 50.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (16%) Velocity 20.0 pts (39%) Breadth 9.4 pts (18%) Claim depth 13.3 pts (26%)

Qualcomm Incorporated · highest

85
Centerline Biomedical · this assignee

51
3D Lighting… · lowest

7

What this shows Centerline's Innovation Score is 50.9/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Centerline?

Each dot is one of Centerline’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Centerline’s own 22.1 claims/patent is ABOVE the 10.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Centerline vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Centerline's grants concentrate

Centerline Biomedical, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 80% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2024. By volume, Centerline sits between Celeritasworks, LLC and Chian YIH Optotech Co., Ltd..

Centerline's three-year grant acceleration

Centerline Biomedical, Inc. shows 8 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Celeritasworks

10
Cellseed

10
Cellspect

10
Cellwize Wireless

10
Centre FOR Develo…

10
Chanel

10
Changwon National…

10
Chian YIH Optotech

10
Centerline Biomed… ◀

10

What this shows Centerline holds 10 patents at rank #25,959, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Centerline

By rank, the assignees closest to #25,959 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Centerline's primary technology class.

Centerline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Centerline Biomedical, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	2	20.0%
2022	4	40.0%
2023	3	30.0%
2024	1	10.0%

Which technologies does Centerline Biomedical, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 8

G06T - Image Data Processing OR Generation, IN General 5

G06F - Electric Digital Data Processing 4

G02B - Optical Elements, Systems OR Apparatus 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

G06V - Image OR Video Recognition OR Understanding 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Centerline Biomedical, Inc.'s patent record in context - here's where to go next.

Centerline Biomedical, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 80% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #25,975 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Centerline Biomedical, Inc. against Celeritasworks, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.